

Co-first authors.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

***Corresponding authors:**

- Lixin Zhu (zhulx6@mail.sysu.edu.cn)
- Department of Colorectal Surgery, Guangdong Institute of Gastroenterology, Guangdong
- Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital,
- Sun Yat-sen University, Guangzhou 510655, P.R. China.
- Tel: 86-199-4625-6235
-
- Zhanju Liu (liuzhanju88@126.com)
- Center for IBD Research, Department of Gastroenterology, The Shanghai Tenth People's Hospital,
- School of Medicine, Tongji University, Shanghai 200072, P. R. China.
- Tel: 86-21-6630-1164
-
- Qing He (heqing5@mail.sysu.edu.cn)
- Departments of Gastroenterology and Nutrition, the Sixth Affiliated Hospital, Sun Yat-sen
- 36 University, Guangzhou 510655, P.R. China.
- Tel: 86-136-0906-1002
-
- Ruixin Zhu (rxzhu@tongji.edu.cn)
- Department of Gastroenterology, The Shanghai Tenth People's Hospital, School of Medicine,
- School of Life Sciences and Technology, Tongji University, Shanghai 200072, P. R. China.
- Tel: 86-21-6598-1041

Abstract

signatures has emerged as potential diagnostic markers for IBD [8-12]. For instance, Pascal et al.

 Notably, species abundance may not be an accurate representative of the microbial functions as reflected by the fact that the nomenclatures of many gut microbial species are currently and constantly being adjusted. In this regard, the diagnostic value of microbial genes and their polymorphisms has become popular subjects of investigation [13-16] (**Fig. 1B**). For example, microbial functional genes outperformed microbial species in distinguishing CRC from controls [14]. Similarly, a recent study demonstrated high accuracy of microbial SNVs for diagnosing CD [17]. Currently, an integrated investigation on multidimensional signatures of CD at species-, gene-and SNV-levels is missing and seems to be warranted in the clinic.

 In this study, with large numbers of whole metagenome sequencing (WMS) samples from multiple cohorts, we constructed diagnostic models for CD and systematically assessed the predictabilities of multidimensional signatures. Candidate biomarkers for CD diagnosis were identified and further validated by qRT-PCR with an independent cohort. Collectively, these results uncover the multidimensional alterations of the microbial communities in CD patients and provide unbiased and robust biomarkers for CD diagnosis.

Model construction

Artificial intelligence (AI) algorithm called feedforward neural network (FNN) was employed to

construct the diagnostic model. In detail, the hidden layers were activated by rectified linear unit

 To test the robustness and generalization of selected optimal model among distinct cohorts, we performed cohort-to-cohort transfer and leave-one-cohort-out (LOCO) validation as described in our previous studies [24, 25]. For cohort-to-cohort transfer, diagnostic models were trained on one single cohort and validated on each of the remaining cohorts. For LOCO validation, one single cohort was set as the validation dataset while all other cohorts were pooled together as the discovery dataset.

Disease specificity assessment of prediction model

- 192 Using non-CD diseases samples of UC, CRC, T2D, LC and PD, we evaluated the disease specificity
- of the predictive model for CD, following the method described by Thomas et al [26]. In detail, we

randomly selected 10 control samples and 10 case samples from non-CD external data and added

- them into the control group in the validation dataset. If the model is specific for CD, the model
- would not perform worse with the addition of a case relative to the addition of the controls, because
- the model does not cover the characteristics of non-CD diseases. We repeated the procedure for 50

times.

Validation of microbial genes by qRT-PCR

201 The gDNA was extracted with the TIANamp Stool DNA Kit (Cat# 4992205, TIANGEN) according to the manufacturer's instructions. The primers used for validation are listed in **Table S4**. To perform the qRT-PCR analysis, the reaction mixture contained the primer pair with concentrations diluted to 0.2 μM and 10 ng gDNA in a 10 μl final volume with the SYBR Green qPCR Mix 205 (Thermo Fisher Scientific). The cycling program was set as indicated: pre-denaturation at 95 °C for 206 10 min; denaturation at 95 °C for 15 s and annealing at 60 °C for 60 s for 40 cycles, followed by melting curve analysis. The qRT-PCR results were quantitated by calculating −ΔΔCt values between candidate genes and the 16S gene. The significance of the comparison between CD and 209 control samples was tested by a two- sided Wilcoxon rank-sum test $(P < 0.05)$.

Statistical analysis

Alpha and beta diversity analysis

- Alpha diversity of taxonomic profiles including Shannon, ACE, Simpson and Chao1 index were
- calculated based on Bray-Curtis distance using R (V4.0.5) "vegan" (V2.5.7) package. Beta diversity
- between groups were calculated by permutational multivariate analysis of variance (PERMANOVA)
- called adonis test, and significance was evaluated with 999 permutations.
-

Co-abundance analysis

Firstly, we generated species abundance profiles of CD and controls, respectively. Then we

employed SparCC [27] to perform co-abundance analysis of differential multi-kingdom species.

221 Correlations between differential multi-kingdom species were determined with 50 iterations. Then

- 222 SparCC resampled the original dataset through bootstrap method to obtain random datasets. Later,
- pseudo-p-values are calculated from these random data sets to assess the significance of the initial
- observation scores. The statistical significance was calculated with 999 permutations. The network
- was visualized with Gephi (V0.9.5).
-

Multidimensional signatures association analysis

 To further explore the potential associations between multi-dimensional signatures, Hierarchical All-against-All association testing (HALLA, V 0.8.20) [28] was performed. We generated species-, gene-, and SNV-profiles of CD patients and controls, respectively. Subsequently, the associations between the species-, gene-, SNV-signatures were calculated in pairs by HALLA. After that, we

merged the output correlation matrices. Correlations with |cor| > 0.4 and *P*-values < 0.05 were used

to constructed the network and visualized with Gephi (V0.9.5).

Results

Characterization of multicohort WMS data and study design

- In this study, we collected eight fecal shotgun metagenomics datasets from published studies to
- characterize the gut microbiome in CD patients compared to healthy controls (**Fig. 1A**). Patients
- treated with antibiotics were excluded. In total, we included 785 samples from CD patients and 456
- healthy control samples across geographically distinct regions from U.S. and China as the discovery
- dataset. In addition, 85 CD samples and 92 controls from three independent cohorts from U.S.,
- Spain and Netherlands were included as the validation dataset. The overall protocol for this study
- (**Fig. 1C**) was based on the workflow of a previous study [24] with modifications.
-

Multidimensional alterations in gut microbial profiles in CD patients

- At species level, we found that alpha and beta diversities were significantly differed between CD
- patients and controls (**Fig. 2A-B**). A total of 80 bacterial species were identified with significantly
- different abundances between CD and control, such as *Escherichia coli*, *Flavonifractor plautii*,
- *Klebsiella pneumoniae* and *Bacteroides intestinalis*. (**Fig. 2C; Table S5**). Besides, 147 non-
- bacterial species including 70 fungus, 42 viruses and 35 archaea exhibited differential abundances
- between CD and controls, such as *Aspergillus rambellii*, *Capronia epimyces*, *Bacteroides phage*
- *B124-14*, *Klebsiella virus KpV80* and *DPANN group archaeon LC1Nh* (**Fig. S1 and Table S5**).

 Further, we investigated the differences in microbial interactions between CD and controls by performing co-abundance analysis via SparCC. Interestingly, interactions among intra-kingdom species were more frequently observed in the network of CD, compared to the network of controls (**Fig. S2**), indicating large scale alterations in the structure and function of the gut microbiome in CD. Next, we assessed the microbial alterations at KO gene level, and identified 497 genes with increased abundance and 1043 genes with decreased abundance in CD patients, such as the genes encoding peptide/nickel transport system permease protein (*ABC.PE.P*), mannose PTS system EIIC component (*manY*), flagellin (fliC) and cellobiose PTS system EIIC component (*celB*) (**Fig. 2E; Table S6**). For better understanding of these differential KO genes, we performed gene set enrichment analysis (GSEA). 59 enriched pathways, including 18 pathways with increased abundances and 41 with decreased abundances in CD patients, were identified (**Fig. S3A and Table S7**). Propanoate metabolism, quorum sensing, phosphotransferase system (PTS) and purine metabolism exhibited increased abundances in CD, while biosynthesis of secondary metabolites, pantothenate and CoA biosynthesis exhibited decreased abundances in CD.

 For microbial SNV level analysis, a total of 7 commonly observed species that have sufficient 271 coverage ($> 3X$) in at least 20% of the samples were annotated, with the number of SNVs ranging from 74 with *Bacteroides rodentium* to 99305 with *Bacteroides vulgatus* (**Fig. S3B and Fig. S4**). A total of 21877 differential SNVs were identified in the seven annotated species (**Fig. S3C**). For

with high SHAP values, suggesting their close association with CD pathology (**Fig. S6A and Table**

S9).

All rights reserved. No reuse allowed without permission.

Gene model achieves superior robustness and generalization

the samples with non-CD diseases on the CD model, indicating that our diagnostic model is specific

for CD.

Outstanding contributions of phosphotransferase system to the diagnostic capability of the

gene model

 To evaluate the respective contributions of each gene set and of key gene feature in the gene model, 342 the KO gene features were grouped by gene set and the importance of each gene set was evaluated as described in Methods section. Relative to the baseline AUC of 0.91, the abundance disturbance of the gene sets quorum sensing, PTS and ABC transporters caused the greatest decrease of AUC in the predictive model by 1.09 to 1.70 percent (**Fig. 4A**). Further, we performed recursive feature elimination by gene sets and reconstructed diagnostic models. We found that the AUC of cross- validation did not decrease significantly until the glycerolipid metabolism gene set was eliminated, which confirmed the important contribution of quorum sensing, PTS, ABC transporters, fructose and mannose metabolism and glycerolipid metabolism to the diagnostic model (**Fig. S10A**). To further strengthen these results, we constructed a sub-model with genes of these five gene sets, which achieved an AUC of 0.89 in cross-validation (**Fig. S10B**). The sub-model displayed decent robustness in internal validations and achieved an average AUC of 0.81 in external validation (**Fig. S10C**). Notably, we found that *celB* was the most important feature in the sub-model (**Table S12**). These results suggest that the above identified gene sets are the key contributors to diagnostic capabilities of the gene model.

Altered interactions within and between each level of microbial signatures in CD

 For a global understanding of the interactions among all the microbial signatures in CD, we investigated the associations among all the microbial signatures via HALLA (**Fig. 5A-B**). In both CD and control networks, considerable associations were observed between KO genes and species, but few observed between SNVs and the other two levels (|correlation| > 0.4) (**Fig. 5B, E**). More associations were observed in the network of CD (206 associations) (**Fig. 5D)**, than in the network of controls (163 associations) (**Fig. 5G; Table S14-15**). Interestingly, there were more negative associations between the gene- and the species-signatures in the control network than that in the CD

 Our work takes advantages of excellent adaptability and learning ability of AI in large dataset and provides an effective non-invasive diagnostic tool with improved discrimination power for CD. However, the interpretability of the AI model is limited, which could be improved with a causal analysis in the future.

Conclusions

- Our global metagenomic analysis unravels the multidimensional alterations of the microbial
- communities in CD and identifies microbial genes as robust diagnostic biomarkers across cohorts.
- These genes are functionally related to the pathogenesis of CD. Future study on these genes may
- lead to an effective non-invasive diagnostic tool for CD.
-

Ethics approval and consent to participate

- All participants provided written informed consent prior to data collection. The study was approved
- by the Institutional Review Board at the Shanghai Tenth People's Hospital, Tongji University,
- Shanghai (No. 20KT863).
-

Consent for publication

- Not applicable.
-

Availability of data and materials

- The data that support the findings of this study are available from the corresponding author, upon
- reasonable request. The code and scripts are available on GitHub
- (https://github.com/tjcadd2020/Diagnosis-for-CD).
-

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

- LZ, ZL, QH and RZ conceived and designed the project. SG and XG drafted the manuscript. RZ,
- DW, ZF, NJ, RS, WG, QH, ZL and LZ revised the manuscript. All authors read and approved the
- final manuscript.

Acknowledgements

- This work was supported by the National Natural Science Foundation of China (82170542 to RZ,
- 92251307 to RZ, 32200529 to DW, 82000536 to NJ), the National Key Research and Development

Program of China (2021YFF0703700/2021YFF0703702 to RZ), and Guangdong Province "Pearl

- River Talent Plan" Innovation and Entrepreneurship Team Project (2019ZT08Y464 to LZ). The
- funders had no role in study design, data collection and analysis, decision to publish, or preparation
- of the manuscript.

Abbreviations

ABC.PE.P: peptide/nickel transport system permease protein; **agaF**: N-acetylgalactosamine PTS

system EIIA component; **AKR1A1**: alcohol dehydrogenase (NADP+); **ALDH**: aldehyde

dehydrogenase (NAD+); **allA**: ureidoglycolate lyase; **AUC**: area under the ROC curve; **CD**:

- Crohn's disease; **celB**: cellobiose PTS system EIIC component; **CRC**: colorectal cancer; **EIIC**:
- enzyme IIC component; **ENA**: European Nucleotide Archive; **fliC**: flagellin; **FNN**: Feedforward
- neural network; **GSEA**: gene set enrichment analysis; **IBD**: inflammatory bowel disease; **impB**:

References

- 1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence
- and prevalence of inflammatory bowel disease in the 21st century: a systematic review of
- population-based studies. Lancet. 2017;390(10114):2769-78.

2. The global, regional, and national burden of inflammatory bowel disease in 195 countries and

- territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet
- Gastroenterol Hepatol. 2020;5(1):17-30.
- 3. Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis, and Management.
- Mayo Clin Proc. 2017;92(7):1088-103.

- 4. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR
- Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD,
- detection of complications. J Crohns Colitis. 2019;13(2):144-64.
- 5. Feld LD, Kirk K, Feld AD. A High Quality Approach to Addressing Complications of
- Endoscopy and Optimizing Risk Management Strategies. Techniques and Innovations in
- Gastrointestinal Endoscopy. 2022.
- 6. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel
- disease. Gastroenterology. 2011;140(6):1817-26 e2.
- 7. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive Protein,
- Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic
- Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J
- Gastroenterol. 2015;110(6):802-19; quiz 20.
- 8. Dubinsky M, Braun J. Diagnostic and Prognostic Microbial Biomarkers in Inflammatory
- Bowel Diseases. Gastroenterology. 2015;149(5):1265-74.e3.
- 9. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al.
- Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655-62.
- 10. Huang Q, Zhang X, Hu Z. Application of Artificial Intelligence Modeling Technology Based
- on Multi-Omics in Noninvasive Diagnosis of Inflammatory Bowel Disease. J Inflamm Res.
- 2021;14:1933-43.

- 11. Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, et al. A microbial
- signature for Crohn's disease. Gut. 2017;66(5):813-22.
- 12. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut
- microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol.
- 2019;4(2):293-305.
- 13. Tierney BT, Tan Y, Kostic AD, Patel CJ. Gene-level metagenomic architectures across
- diseases yield high-resolution microbiome diagnostic indicators. Nat Commun. 2021;12(1):2907.
- 14. Liu NN, Jiao N, Tan JC, Wang Z, Wu D, Wang AJ, et al. Multi-kingdom microbiota analyses
- identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nat
- Microbiol. 2022;7(2):238-50.
- 15. Yan Y, Nguyen LH, Franzosa EA, Huttenhower C. Strain-level epidemiology of microbial
- communities and the human microbiome. Genome Med. 2020;12(1):71.
- 16. Ma C, Chen K, Wang Y, Cen C, Zhai Q, Zhang J. Establishing a novel colorectal cancer
- predictive model based on unique gut microbial single nucleotide variant markers. Gut Microbes.
- 2021;13(1):1-6.
- 17. Jiang S, Chen D, Ma C, Liu H, Huang S, Zhang J. Establishing a novel inflammatory bowel
- disease prediction model based on gene markers identified from single nucleotide variants of the
- intestinal microbiota. iMeta. 2022;1(3).
- 18. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome Biol.
- 2019;20(1):257.

- 19. Li D, Liu C-M, Luo R, Sadakane K, Lam T-W. MEGAHIT: an ultra-fast single-node solution
- for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics. 2015;31(10):1674-6.
- 20. Hyatt D, Chen G-L, LoCascio PF, Land ML, Larimer FW, Hauser LJ. Prodigal: prokaryotic
- gene recognition and translation initiation site identification. BMC Bioinformatics. 2010;11(1):119.
- 21. Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation
- sequencing data. Bioinformatics. 2012;28(23):3150-2.
- 22. Nayfach S, Rodriguez-Mueller B, Garud N, Pollard KS. An integrated metagenomics pipeline
- for strain profiling reveals novel patterns of bacterial transmission and biogeography. Genome Res.
- 2016;26(11):1612-25.
- 23. Scott M. Lundberg S-IL. A Unified Approach to Interpreting Model Predictions. NIPS'17:
- Proceedings of the 31st International Conference on Neural Information Processing Systems.
- 2017:4768–77.
- 24. Gao W, Chen W, Yin W, Zhu X, Gao S, Liu L, et al. Identication and validation of microbial
- biomarkersfrom cross-cohort datasets using xMarkerFinder. Protocol Exchange. 2022.
- 25. Wu Y, Jiao N, Zhu R, Zhang Y, Wu D, Wang AJ, et al. Identification of microbial markers
- across populations in early detection of colorectal cancer. Nat Commun. 2021;12(1):3063.
- 26. Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, et al. Metagenomic
- analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a
- link with choline degradation. Nat Med. 2019;25(4):667-78.

- 27. Friedman J, Alm EJ. Inferring Correlation Networks from Genomic Survey Data. PLOS
- Computational Biology. 2012;8(9):e1002687.
- 28. Ghazi AR, Sucipto K, Rahnavard G, Franzosa EA, McIver LJ, Lloyd-Price J, et al. High-
- sensitivity pattern discovery in large, paired multi-omic datasets. bioRxiv. 2021:2021.11.11.468183.
- 29. Kim S, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization resistance,
- and enteric pathogens. Immunol Rev. 2017;279(1):90-105.
- 30. Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways
- in inflammatory bowel disease. Nat Rev Microbiol. 2019;17(8):497-511.
- 31. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions:
- metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1-24.
- 32. Lengeler JW, Jahreis K. Bacterial PEP-dependent carbohydrate: phosphotransferase systems
- couple sensing and global control mechanisms. Contrib Microbiol. 2009;16:65-87.
- 33. Västermark A, Saier MH, Jr. The involvement of transport proteins in transcriptional and
- metabolic regulation. Curr Opin Microbiol. 2014;18:8-15.
- 34. Saier MH, Jr. The Bacterial Phosphotransferase System: New Frontiers 50 Years after Its
- Discovery. J Mol Microbiol Biotechnol. 2015;25(2-3):73-8.
- 35. Aymeric L, Donnadieu F, Mulet C, du Merle L, Nigro G, Saffarian A, et al. Colorectal cancer
- specific conditions promote Streptococcus gallolyticus gut colonization. Proc Natl Acad Sci U S A.
- 2018;115(2):E283-e91.

- 36. Lin Y, Lau HC, Liu Y, Kang X, Wang Y, Ting NL, et al. Altered Mycobiota Signatures and
- Enriched Pathogenic Aspergillus rambellii Are Associated With Colorectal Cancer Based on
- Multicohort Fecal Metagenomic Analyses. Gastroenterology. 2022;163(4):908-21.
- 37. Coker OO, Nakatsu G, Dai RZ, Wu WKK, Wong SH, Ng SC, et al. Enteric fungal microbiota
- dysbiosis and ecological alterations in colorectal cancer. Gut. 2019;68(4):654-62.
- 38. Wu M-C, Chen Y-C, Lin T-L, Hsieh P-F, Wang J-T, Camilli A. Cellobiose-Specific
- Phosphotransferase System of Klebsiella pneumoniae and Its Importance in Biofilm Formation and
- Virulence. Infection and Immunity. 2012;80(7):2464-72.
- 39. Rashid T, Ebringer A, Wilson C. The role of Klebsiella in Crohn's disease with a potential for
- the use of antimicrobial measures. Int J Rheumatol. 2013;2013:610393.
- 40. Jeckelmann JM, Erni B. The mannose phosphotransferase system (Man-PTS) Mannose
- transporter and receptor for bacteriocins and bacteriophages. Biochim Biophys Acta Biomembr.
- 2020;1862(11):183412.
- 41. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the
- human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med.
- 2009;1(6):6ra14.
-

Figure Legends

 Fig. 1. Overview of the fecal samples included in this study and the analysis protocol. A We collected a total of 1418 samples from 8 cohorts with fecal shotgun metagenomic data. The discovery dataset included D1, D2, D3, D4 and D5. The validation dataset included V1, V2 and V3.

 circles represent the GC-content (cyan indigo lines), sequencing depth (purple lines) and sites of differential SNVs (brown points) in the genome, respectively. **E** UpSet plot showing the number of differential KO genes identified via MaAsLin2 in each dataset and those shared by the datasets. The number above each column represents the intersection size of differential KO genes. The connected dots represent the common differential genes across connected cohorts. The set size on the right represents the number of differential genes in each cohort. **Fig. 3. The performance of diagnostic models constructed with multidimensional signatures.**

 A The ROC curves from ten-fold cross-validation of species-, gene-, SNV- and combined diagnostic models. **B** The AUCs of species-, gene-, SNV- and combined diagnostic models in external validation dataset. **C** The AUCs of each model in cohort-to-cohort validation. Each number represents the average AUC of validation with the cohort specified by its column tag as the training cohort, and all other cohorts as the validation cohorts. **D** The AUC of each model in LOCO validation. Each number represents the resulting AUC of validation with the cohort specified by its column tag as the validation cohort while the other cohorts combined as training cohort. **E** Prediction performances as AUC values on the validation cohorts when adding an external set of control and case samples from non-CD disease cohorts (ulcerative colitis (UC), colorectal cancer (CRC), type-2 diabetes (T2D), liver cirrhosis (LC) and Parkinson's disease (PD)). Gray and colored bars are the AUCs after adding control and case samples from the non-CD disease cohorts, respectively.

signatures of different levels: species (green), KO genes (yellow), and SNVs (brown). Red line

indicates positive interaction; and blue line indicates negative interaction (|correlation|>0.4, FDR <

0.05). **C** Density distribution of correlations between different levels of signatures (FDR < 0.05) in

the control network. **D** Density distribution of node degrees for different levels of signatures

((|correlation|>0.4, FDR < 0.05) in the control network. **E** Numbers of edges (|correlation|>0.4, FDR

- 668 < 0.05) in the control network. **F** Density distribution of correlations between different levels of
- 669 signatures (FDR < 0.05) in the CD network. **G** Density distribution of node degrees for different
- 670 levels of signatures ((|correlation|>0.4, FDR < 0.05) in the CD network. **H** Number of edges
- 671 ($|correlation| > 0.4$, FDR < 0.05) in the CD network.

